Sigma-Aldrich to sell small molecule compounds from Pfizer
Sigma-Aldrich will sell approximately 100 Pfizer-developed small molecule compounds
Sigma-Aldrich will sell approximately 100 Pfizer-developed small molecule compounds to life science researchers for target characterisation, assay development, screening and in vivo animal model applications.
The companies have agreed to make available the Pfizer compounds, which include patented and approved drug molecules such as atorvastatin, sildenafil and celecoxib, to researchers while still on patent, in some cases for the first time.
‘This multi-compound deal not only enriches our extensive portfolio of products with authentic Pfizer material, but also provides valuable resources that will enable our customers to modulate their protein targets, facilitating further advances in cellular and pathway biology,’ said David Smoller, president of Sigma Life Science's Research Biotech Business Unit.
‘Working with Sigma-Aldrich we are able to make authentic Pfizer compounds more readily available to the research community,’ added Rick Connell, vice president and worldwide head of Pfizer’s external research solutions centre of excellence.
The Pfizer compounds will be sold worldwide directly through Sigma-Aldrich as in-stock, pre-packaged items and, upon request, in bulk, and will also be mapped to genes and associated pathways and interactors through Sigma-Aldrich's online search platform, ‘Your Favorite Gene powered by Ingenuity’.
Sigma-Aldrich says it will add further Pfizer compounds on a regular basis.
